Evan C. Callihan

HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors

Mary E. Molloy, Wade H. Aaron, Manasi Barath et al. · Molecular Cancer Therapeutics · 2024 · 29 citations · Full text

Life Sciences, Immunology, Oncology +17

Preclinical and Nonclinical Characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for the Treatment of Multiple Myeloma

Che‐Leung Law, Wade H. Aaron, Rick Austin et al. · Blood · 2018 · 19 citations

Life Sciences, Immunology, Oncology +14

Abstract C033: HPN328: An anti-DLL3 T cell engager for treatment of small cell lung cancer

Wade H. Aaron, Richard J. Austin, Manasi Barath et al. · Molecular Cancer Therapeutics · 2019 · 14 citations

Life Sciences, Immunology, Oncology +12

Chromosome fusions triggered by noncoding RNA

John R. Bracht, Xing Wang, Keerthi Shetty et al. · RNA Biology · 2016 · 11 citations · Full text

Life Sciences, Genetics, Molecular Biology +14

Abstract 933: ProTriTAC is a modular and robust T cell engager prodrug platform with therapeutic index expansion observed across multiple tumor targets

Sen Lin, Sony Sotelo Rocha, Kathryn Kwant et al. · Cancer Research · 2021 · 10 citations

Pharmacy, Medicinal Chemistry, Oncology +17